Lung cancer trials in Italy

In Italy 272 Also abroad 2746

272 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Where
Bergamo, Genoa, Milan, Monza, Padova, Pavia, Ravenna, Rome, Rozzano
Age
18 years and over
People
675 worldwide
Run by
AstraZeneca
See details and how to joinNCT06357533 · EU 2023-505077-32-00
Phase 3Taking people
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC
Where
Florence, Leghorn, Legnano, Monza, Peschiera del Garda, Rome
Age
18 years and over
People
1,160 worldwide
Run by
AstraZeneca
See details and how to joinNCT06627647 · EU 2024-515008-38-00
Phase 1/2Taking people
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
Where
Milan, Ravenna, Roma, Verona
Age
18 years and over
People
235 worldwide
Run by
Alentis Therapeutics AG
See details and how to joinNCT06747585 · EU 2024-515459-39-00
Phase 3Taking people
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy
Where
Meldola, Milan, Novara, Pavia, Prato, Siena, Verona
Age
18 years and over
People
390 worldwide
Run by
ETOP IBCSG Partners Foundation
See details and how to joinNCT06931717 · EU 2024-519901-36-00
Phase 1/2Taking people
A Platform Study in Non-Small Cell Lung Cancer (NSCLC)
Where
Milan, Orbassano, Pavia, Rome
Age
18 years and over
People
152 worldwide
Run by
AstraZeneca
See details and how to joinNCT06996782 · EU 2024-519786-22-01
No phaseTaking people
Characteristics of Advanced LUNG CANCER at the tIme of Diagnosis in a Large Italian Cohor
Where
Roma
Age
18 years and over
People
1,000
Run by
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT06076005
Phase 1/2Taking people
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Where
Ancona, Bologna, Meldola, Milan, Orbassano, Rome
Age
18 years and over
People
252 worldwide
Run by
AbbVie
See details and how to joinNCT06772623 · EU 2024-514465-18-00
Phase 3Taking people
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Where
Bari, Florence, Genoa, Meldola, Naples, Orbassano, Padova, Parma, Pavia, Rome, Varese
Age
18 years and over
People
630 worldwide
Run by
Mirati Therapeutics Inc.
See details and how to joinNCT06875310 · EU 2024-515698-85-00
Phase 2Taking people
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer
Where
Bologna, Milan, Naples, Orbassano, Padova, Rome
Age
18 years and over
People
180 worldwide
Run by
AbbVie
See details and how to joinNCT07155174 · EU 2024-517490-24-00
Phase 2Taking people
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Where
Bergamo, Genova, Naples, Verona
Age
18 years and over
People
740 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00
Phase 2Taking people
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Where
Aviano, Candiolo, Meldola, Milan, Ravenna, Rome
Age
18 years and over
People
131 worldwide
Run by
CatalYm GmbH
See details and how to joinNCT07246863 · EU 2024-516794-70-00
Phase 3Taking people
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) after immunotherapy failure.
Where
Genoa, Lecce, Lucca, Meldola, Milan, Naples, Novara, Orbassano, Padova, Peschiera del Garda, Pisa, Rimini, Rome, Rozzano, Siena
Age
18 years and over
People
340 worldwide
Run by
OSE Immunotherapeutics
See details and how to join2023-509340-10-00
Phase 3Taking people
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Where
Bologna, Candiolo, Fano, Genoa, Leghorn, Milan, Misterbianco, Orbassano, Rome, Varese, Verona
Age
18 years and over
People
686 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06899126 · EU 2024-515658-26-00
Phase 3Taking people
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
Where
Aviano, Candiolo, Catania, Ferrara, Genoa, Milan, Naples, Novara
Age
18 years and over
People
750 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07361510 · EU 2025-523586-18-00
Phase 2Taking people
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Where
Bari, Bergamo, Milan, Misterbianco, Ravenna, Rozzano
Age
18 years and over
People
160 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07680764 · EU 2026-525170-19-00
No phaseTaking people
Study of Collection and Analysis of Clinical, Anamnestic, Functional, Biological Data Through the Support of Artificial Intelligence to Evaluate the Possibility of Defining a Digital Twin of the Lung (LUCE)
Where
Peschiera del Garda
Age
18 years and over
People
1,000
Run by
Casa di Cura Dott. Pederzoli
See details and how to joinNCT07517393
Phase 1Taking people
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
Where
Milan, Naples
Age
18 years and over
People
64 worldwide
Run by
Novartis Pharma AG
See details and how to join2024-518348-19-00
Phase 2Taking people
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
Where
Aviano, Brescia, Florence, Genoa, Meldola, Milan, Monza, Padova, Perugia, Pisa, Rome, Rozzano
Age
18 years to 95 years
People
630 worldwide
Run by
AstraZeneca
See details and how to joinNCT05061550 · EU 2023-508852-21-00
Phase 3Taking people
Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer
Where
Aviano, Candiolo, Lucca, Milan, Naples, Pesaro, Peschiera del Garda, Roma, Treviglio
Age
18 years and over
People
695 worldwide
Run by
Gilead Sciences
See details and how to joinNCT06801834
Phase 2Taking people
Randomized phase II trial of Cemiplimab plus OSE2101 (TEDOPI®) as maintenance therapy in ctDNA positive NSCLC.
Where
Aviano, Bari, Catania, Genoa, Meldola, Modena, Monza, Naples, Novara, Pavia, Perugia, Reggio Emilia, Rome, Varese, Verona
Age
18 years and over
People
90
Run by
Fondazione Ricerca Traslazionale
See details and how to join2024-519262-42-00
Phase 3Taking people
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
Where
Ancona, Aviano, Bari, Bologna, Candiolo, Catania, Genoa, Lucca, Meldola, Milan, Monza, Naples, Parma, Peschiera del Garda, Ravenna, Reggio Emilia, Rome, Siena, Verona
Age
18 years and over
People
263 worldwide
Run by
Zai Lab (US) LLC
See details and how to join2025-522818-23-00
Phase 2/3Not yet taking people in Italy
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations”
Where
Alba, Alexandria, Asti, Aviano, Bagno a Ripoli, Bari, Bergamo, Bolzano, Brescia, Cagliari, Catania, Ferrara, Florence, Genoa, Grosseto, Lecce, Meldola, Milan, Misterbianco, Monza, Naples, Negrar, Novara, Olbia, Orbassano, Padova, Parma, Pavia, Pesaro, Peschiera del Garda, Prato, Ravenna, Reggio Emilia, Rome, Rozzano, San Giovanni Rotondo, Saronno, Trento, Treviso, Turin, Udine, Varese, Verona
Age
18 years and over
People
962
Run by
Universita' Degli Studi Di Torino
See details and how to join2026-525268-16-00
Phase 1/2Taking people
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Where
Milan, Orbassano, Ravenna, Rome
Age
18 years and over
People
616 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT06162221 · EU 2025-521147-21-00
Phase 2Taking people
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC
Where
Aviano, Candiolo, Meldola, Milan, Ravenna, Rome
Age
18 years and over
People
107 worldwide
Run by
CatalYm GmbH
See details and how to joinNCT07098988 · EU 2024-516792-32-01
No phaseTaking people
PRophylactic Cerebral Irradiation or Active MAgnetic Resonance Imaging Surveillance in Small-cell Lung Cancer Patients (PRIMALung Study)
Where
Genova, Legnago, Pavia, Treviglio, Verona
Age
18 years and over
People
600 worldwide
Run by
European Organisation for Research and Treatment of Cancer - EORTC
See details and how to joinNCT04790253